Posted by Michael Wonder on 14 Nov 2016
AbbVie's Humira (adalimumab) receives CHMP positive opinion to treat adolescents with hidradenitis suppurativa, a chronic inflammatory skin disease
14 November 2016 - If approved by the European Commission, Humira will be the first and only treatment option for patients aged 12 and older with hidradenitis suppurativa, a painful, chronic inflammatory skin disease.
AbbVie today announced that the CHMP of the EMA has granted a positive opinion for Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.
If approved, Humira will become the first and only biologic treatment option for patients 12 years of age and older. Humira was approved for adults with moderate to severe HS by the European Commission in July 2015.
